Company intelligence / Profile preview
Lipigon Pharmaceuticals
Umeå, N/A, Swedenlipigon.se ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Lipigon’s lead candidate, Lipisense®, is an RNA-based antisense oligonucleotide targeting ANGPTL4 to lower triglycerides. It has completed Phase I and entered Phase II trials in early 2024 for severe hypertriglyceridemia. The company also has preclinical programs in ARDS, dyslipidemia, and gene therapy for lipodystrophy. Early results show promise for first-in-class mechanisms addressing unmet needs in lipid-related diseases.[1][7]
- Therapeutic areas
- PulmonologyCardiovascularEndocrinologyMetabolic Disorders
- Modalities
- Antisense oligonucleotides (ASOs)RNA therapeuticsSmall moleculesGene therapy[3][6][8][10]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
HitGen Inc. – small molecule collaboration for dyslipidemia [1][3]Secarna Pharmaceuticals – LNAplus™ platform licensing/collaboration [8]LINK Medical – CRO partner supporting clinical development [7]
Beyond the preview
Go deeper on Lipigon Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lipigon Pharmaceuticals.